Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Elson

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Journal of Cancer Research and Clinical Oncology|May 18, 2001
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinomaT Olencki, D Peereboom, L Wood, et al.
Oncogene|October 15, 2011
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancerV Cheriyath, M A Kuhns, B S Jacobs, et al.
The Journal of Urology|February 24, 2009
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomyD R Shepard, R Dreicer, J Garcia, et al.
Surgery|December 1, 1991
Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinomaR A Decker, P Elson, T F Hogan, et al.
Gynecologic Oncology|October 19, 2001
Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasiaJ Belinson, Y L Qiao, R Pretorius, et al.
JAMA|September 5, 1998
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancersY Xu, Z Shen, D W Wiper, et al.
Investigational New Drugs|August 25, 2000
Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomasT Chidiac, G T Budd, R Pelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapyR M Bukowski, P Rayman, R Uzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2006
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinomaT K Choueiri, Bi Rini, J A Garcia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findingsR M Bukowski, T Olencki, H Gunn, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Journal of Cancer Research and Clinical Oncology|May 18, 2001
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinomaT Olencki, D Peereboom, L Wood, et al.
Oncogene|October 15, 2011
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancerV Cheriyath, M A Kuhns, B S Jacobs, et al.
The Journal of Urology|February 24, 2009
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomyD R Shepard, R Dreicer, J Garcia, et al.
Surgery|December 1, 1991
Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinomaR A Decker, P Elson, T F Hogan, et al.
Gynecologic Oncology|October 19, 2001
Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasiaJ Belinson, Y L Qiao, R Pretorius, et al.
JAMA|September 5, 1998
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancersY Xu, Z Shen, D W Wiper, et al.
Investigational New Drugs|August 25, 2000
Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomasT Chidiac, G T Budd, R Pelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapyR M Bukowski, P Rayman, R Uzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2006
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinomaT K Choueiri, Bi Rini, J A Garcia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findingsR M Bukowski, T Olencki, H Gunn, et al.
Pageof 6